April 13, 2023 12:01 AM EDTUpdated 06:47 AM

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Venture capital investments in biotech and pharma hit a more than three-year low last quarter as a prolonged market downturn forced difficult next-step decisions for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Bio­phar­ma ven­ture fund­ing falls to the low­est to­tal since 2019 as star­tups pon­der al­ter­na­tive paths

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths